NCT01371851

Doxazosin for Psychostimulant Dependence

Clinical Efficacy of Doxazosin for Psychostimulant Dependence

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University of Arkansas · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can dredge cocaine use relative to placebo in psychostimulant dependent participants enrolled in an 8-week, randomized, double blind, placebo-controlled outpatient clinical trial. Our hypothesis is that doxazosin will reduce cocaine use relative to placebo in psychostimulant dependent participants.

Conditions

• Methamphetamine or Cocaine Dependence

Interventions

Type	Name	Description
DRUG	Doxazosin extended release	initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.

Timeline

• Start date: 2011-06-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2011-06-13
• Last updated: 2015-07-27
• Results posted: 2015-07-27

Locations

1 site across 1 country: United States